Cargando…
VBID, the PPACA, and FREEE Medications: Did Politics Trump the Evidence About Cost Sharing?
The evidence available to date suggests that copayment reductions/waivers provided to commercially insured populations, especially when applied in primary prevention and/or to brand drugs in therapy classes with generic alternatives, are unlikely to yield meaningful health improvements and may direc...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Academy of Managed Care Pharmacy
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438088/ https://www.ncbi.nlm.nih.gov/pubmed/22380473 http://dx.doi.org/10.18553/jmcp.2012.18.2.146 |